Detalhe da pesquisa
1.
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Cancer
; 128(24): 4203-4212, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259380
2.
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(8): 1126-1138, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34237250
3.
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Cancer Discov
; 9(3): 384-395, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30487236
4.
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Clin Cancer Res
; 23(12): 2981-2990, 2017 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011461
5.
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clin Cancer Res
; 10(18 Pt 1): 6086-93, 2004 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15447994
6.
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
J Clin Oncol
; 29(3): 287-93, 2011 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21135284
7.
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
J Clin Oncol
; 28(15): 2598-603, 2010 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20385980
8.
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
J Clin Oncol
; 26(2): 204-10, 2008 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18182663